Immunovia publishes the annual report for the financial year 2017
Mats Grahn, CEO, comments: ”In 2017, Immunovia resolutely worked towards taking the company’s patented, blood-based pancreatic cancer test IMMray® PanCan-d to the market. The main activities have been focused on prospective clinical studies, certifications, accreditations and to scale up production capacity, both for the product itself and for laboratory analysis. All the efforts are targeted to achieve sales during 2018.
Major highlights include:
- Final study data showed that IMMray® biomarkers distinguish SLE and Rheumatoid arthritis from other autoimmune diseases with an accuracy of 96 and 89 percent.
- At the beginning of the year, the University of Michigan joined the Pancreatic Cancer Center as a new partner in Immunovia’s global prospective validation study PanFAM-1, targeting to validate Immunova’s blood-based test, IMMray® PanCan-d. Sahlgrenska became the first Swedish participant and University of Pittsburgh joined later on.
- Immunovia biomarker signature obtained a patent in Japan.
- Immunovia established headquarter for US operations and an accredited reference laboratory in Marlborough, Boston. An US subsidiary was established in 2015.
- Immunovia initiated a collaboration with scientists at Lund University’s Diabetes Center (LUDC) to validate IMMray® PanCan-d in the high risk group of newly diagnosed type 2 diabetes patients 50 years or older (NOD).
- Immunovia initiated the largest study of diabetic patients in a prospective pancreatic cancer study called PanDIA-1.
- Immunovia initiated a large-scale collaboration with Linköping University on the discovery of autoimmune biomarkers.
- Immunovia received a grant of SEK 4.9 million from Swelife for pancreatic cancer studies in collaboration with the Create Health Translational Center at Lund University. A consortium with Lund University, Uppsala University, Lund University Diabetes Center, Uppsala Region and Region Skåne has received a supportive grant of 7.6 MSEK from Swelife.
- University College London Hospital initiated the collection of blood samples to evaluate Immunova’s IMMray® PanCan-d for patients with early symptoms suggestive of pancreatic cancer.
- The company completed the required preparation for listing on the Nasdaq Stockholm main list. The application was submitted at the end of the year. ”
The Swedish annual report is available on Immunovia’s website: immunovia.com/sv/investerare/finansiella-rapporter/
For more information, please contact:
Mats Grahn Chief Executive Officer, CEO, Immunovia
Tel.: +46-70-5320230 Email: firstname.lastname@example.org
Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source: www.immunovia.com)
Immunovia’s shares (IMMNOV) are listed on Nasdaq First North in Stockholm and Wildeco is the company’s Certified Adviser. For more information, please visit www.immunovia.com